Showing 421-430 of 10531 results for "".
Why It’s Critical to Distinguish Between Rosacea Subtypes for Best Results
https://practicaldermatology.com/conferences/maui-derm-2024/why-its-critical-to-distinguish-between-rosacea-subtypes-for-best-results/20245/In the Acne and Rosacea Updates symposium, Hilary Baldwin, MD, explained how she evaluates and treats rosacea with phenotypic therapies based on which aspects of the disease patients are most concerned about.If you had to pick one—skydiving, bungee jumping, or scuba diving—which would you do?
https://practicaldermatology.com/topics/general-topics/if-you-had-to-pick-one-skydiving-bungee-jumping-or-scuba-diving-which-would-you-do/19831/Bruce Strober, MD says his choice is the one that offers him a whole new experience that he's never seen before. Watch now to learn his choice.Gettin' Social With It
https://practicaldermatology.com/topics/practice-management/gettin-social-with-it/19728/An online presence is important, maybe even essential. But there are right and wrong ways to approach social media marketing. Joel Cohen, MD talks to Risa Luksa about the practices and pitfalls of social media.Surgery Not Required?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/surgery-not-required/19723/Patients increasingly want non-surgical options for skin tightening. Fortunately, a plethora of highly effective options exist, from ultrasound to radiofrequency, according to Mitchel Goldman, MD.The Science Driving Topicals Into the Future
https://practicaldermatology.com/topics/psoriasis/the-science-driving-topicals-into-the-future/19721/On the therapeutic front, one topic Neal Bhatia, MD is paying particularly close attention to is recent advances in vehicle science, which offer novel and intriguing strategies to improve delivery of topical applications to and through the skin.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Shifting Paradigms on Lentigo Maligna
https://practicaldermatology.com/conferences/maui-derm-2024/shifting-paradigms-on-lentigo-maligna/20255/According to Ashfaq Marghoob, MD, current research supports individualizing treatment of lentigo maligna (LM) based on what is the best therapeutic option, from active surveillance to surgery to radiation to imiquimod.SCALE 2024: Dr. Michael Gold Recaps the Show and Previews 2025
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michael-gold-recaps-show-and-previews-2025/26751/Michael Gold, MD, FAAD, Course Co-Director for Music City SCALE, discusses the growth of the event over the years, highlights from 2024, and what to expect next year.Addressing Skin Changes During Menopause: An Update
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/addressing-skin-changes-during-menopause-an-update/20220/New York City-based dermatologist Ellen Gendler, MD, shares pearls from her recent talk at the 2023 annual meeting of the Menopause Society including the current thinking on how to address the effects of diminished estrogen on skin.GEP Testing for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-for-cutaneous-squamous-cell-carcinoma/35599/Emily Ruiz, MD, MPH, FAAD, director of the High-Risk Cancer Clinic at Dana-Farber Cancer Institute, discusses utilizing gene expression profiling (GEP) to risk stratify tumors in cutaneous squamous cell carcinoma patients.